Ciprofloxacin hydrochloride monohydrate
(Synonyms: 环丙沙星盐酸盐一水合物; Bay-09867 hydrochloride monohydrate) 目录号 : GC63671
A fluoroquinolone antibiotic
Cas No.:86393-32-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ciprofloxacin is a fluoroquinolone antibiotic.1 It is active against a variety of Gram-positive and Gram-negative bacteria in vitro, including S. aureus, L. monocytogenes, P. aeruginosa, Legionella, N. gonorrhoeae, and H. pylori (MIC50s = 0.004-1 ?g/ml).2 It is also active against clinical isolates of Bacteroides, Fusobacterium, Eubacterium, Actinomyces, Peptococcus, Peptostreptococcus, and Streptococcus in vitro (MIC50s = 0.5-2 ?g/ml).3 Ciprofloxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 13.5 and 5.76 ?g/ml, respectively).4 It reduces mortality in mouse models of intraperitoneal E. coli, P. vulgaris, K. pneumoniae, P. aeruginosa, and S. aureus infection (ED90-100s = 1-5, 2.5-5, 5-10, 20-40, and 80 mg/kg, respectively) and prevents mortality in a mouse model of subcutaneous S. typhimurium infection at 10 mg/kg.5,6 Formulations containing ciprofloxacin have been used in the treatment of bacterial infections.
1.Drlica, K., and Zhao, X.DNA gyrase, topoisomerase IV, and the 4-quinolonesMicrobiol. Mol. Biol. Rev.61(3)377-392(1997) 2.Nilius, A.M., Shen, L.L., Hensey-Rudloff, D., et al.In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinoloneAntimicrob. Agents Chemother.47(10)3260-3269(2003) 3.Bansal, M.B., and Thadepalli, H.Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitroAntimicrob. Agents Chemother.31(4)619-621(1987) 4.Takei, M., Fukuda, H., Kishii, R., et al.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob. Agents Chemother.45(12)3544-3547(2001) 5.Easmon, C.S.F., Crane, J.P., and Blowers, A.Effect of ciprofloxacin on intracellular organisms: In-vitro and in-vivo studiesJ. Antimicrob. Chemother.18 (Suppl D)43-48(1986) 6.Zeiler, H.J., and Grohe, K.The in vitro and in vivo activity of ciprofloxacinEur. J. Clin. Microbiol.3(4)339-343(1984)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5919 mL | 12.9594 mL | 25.9188 mL |
| 5 mM | 0.5184 mL | 2.5919 mL | 5.1838 mL |
| 10 mM | 0.2592 mL | 1.2959 mL | 2.5919 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。